Japan vs United States: The number of people with susceptibility test result for rifampicin
Japan
4,343
in 2021
United States
4,814
in 2021
Japan rank
32nd
United States rank
30th
The number of people with susceptibility test result for rifampicin over time
- Japan
- United States
How they compare
United States currently reports 4,814 against 4,343 in Japan, a difference of 471.
That makes United States's figure about 1.1 times Japan's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Japan ahead.
Japan ranks 32nd and United States ranks 30th of 155 countries.
Japan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Japan | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,026 | 5,218 | 1,808 | Japan |
| 2020s | 4,642 | 4,592 | 50.5 | Japan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Japan or United States?
- United States, at 4,814 against 4,343 in Japan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Japan and United States?
- 471, with United States ahead.
- How many years of comparable data are there for Japan and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Japan and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Japan ranks 32nd and United States ranks 30th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.